SAN DIEGO — Biolinq, a healthcare technology company developing precision biosensors for metabolic health, has closed a $100 million Series C financing round to support the commercial launch of its intradermal glucose sensor platform. The round was led by Alpha Wave Ventures with participation from existing investors, including RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical, and Features Capital.
The new funding will enable Biolinq to complete its U.S. pivotal clinical trial and advance through the regulatory approval process as the company moves closer to commercial readiness. The company’s biosensor is designed to offer effortless glucose monitoring for people with Type 2 diabetes not using insulin, combining metabolic insights with intuitive feedback.
“This financing strengthens our commercial readiness as we pursue regulatory approval for the first intradermal glucose sensor that integrates activity and sleep data into a single wearable device,” said Rich Yang, CEO of Biolinq. “Over the last decade, our team has developed a biosensor platform aimed at inspiring healthier living by providing meaningful context around metabolic health.”
Biolinq’s initial product is a small, wearable sensor patch placed on the upper forearm that continuously measures glucose levels just beneath the skin using an array of electrochemical sensors. The device features a color-changing indicator light that offers users real-time feedback on glucose fluctuations, designed to help people stay informed and make proactive health decisions.
The company’s platform is built to expand beyond glucose sensing, with future capabilities aimed at monitoring additional metabolic biomarkers. This next-generation approach to biowearables could provide a more comprehensive picture of health, according to the company.
“Biolinq has brought together top talent from biosensors, consumer electronics, and semiconductor manufacturing to redefine the biowearables category,” said Rick Gerson, Chairman of Alpha Wave Global. “With its differentiated product, Biolinq is poised to make a significant impact in the growing biosensor market.”
Dan Bradbury, Chairman of Biolinq, emphasized the platform’s potential to help millions of people. “Biolinq’s technology is making glucose data simpler and more accessible, unlocking a new era of biosensing to support better metabolic health for those living with Type 2 diabetes,” he said.
Biolinq’s intradermal glucose sensor is currently investigational and has not yet received clearance from the U.S. Food and Drug Administration or other regulatory agencies. The company plans to use the Series C funds to finalize clinical studies and prepare for regulatory submission.
